Desidustat in non-dialysis CKD patients: A randomized study
2022;32(4):323–330
Advancing the
Management of
ANAEMIA
IN CHRONIC
KIDNEY DISEASE
An oral HIF-PH inhibitor designed to help improve haemoglobin levels in CKD patients through stimulation of endogenous erythropoietin production.
For use in appropriate patients under medical supervision.Oral Therapy
Convenient once-daily oral administration
HIF-PH Inhibitor
Targets the underlying cause of anaemia in CKD
CKD Anaemia Management
Improves haemoglobin levels effectively
Dialysis & Non-Dialysis Patients
Designed for a broad range of CKD patients
16.0
Target range
16g/dl
16g/dl
A New Approach to CKD-ASSOCIATED ANAEMIA
OXEMIA™ (Desidustat) is developed for the management of anaemia associated with Chronic Kidney Disease (CKD). By targeting the hypoxia-inducible factor pathway, OXEMIA™ supports endogenous erythropoietin production and promotes erythropoiesis.
The oral formulation offers convenience for both dialysis and non-dialysis CKD patients while helping support haemoglobin management goals.
HOW OXEMIA™ WORKS
OXEMIA™ acts by inhibiting hypoxia-inducible factor prolyl hydroxylase (HIF-PH), stabilizing HIF and activating the body's natural response to hypoxia.
Increased endogenous
erythropoietin production
Enhanced iron
metabolism
Improved red blood
cell production
Support for haemoglobin
level management
16.0
Target range
16g/dl
16g/dl
Understanding anaemia
in chronic kidney disease
When kidneys are not working as well as they should, the body may produce fewer red blood cells. Understanding the signs is the first step toward a better conversation.
Haemoglobincarries oxygen
O2Oxygen
HbRed blood cells
CKDKidney health
Lower haemoglobin
CKD may reduce the body’s natural erythropoietin production.
Daily impact
Fatigue and breathlessness can disrupt everyday routines.
Track your Hb
Regular monitoring can help guide the right management approach.
Common symptoms
Notice the signs. Start the conversation.
Persistent fatigue
Shortness of breath
Difficulty concentrating
Low energy
Personalized dosing.
Optimized outcomes.
Oxemia dosing is titrated based on Hb response and CKD stage to help achieve and maintain target Hb with minimal dose adjustments.
+
Doctor Recommendation
• Titrate dose gradually to achieve target Hb and avoid rapid increases.
• Individualize based on response and tolerability.
Select CKD Stage
Recommended Starting Dose
CKD Stage
25 mg
50 mg
100 mg
Stage 5 ND
Once daily
Once daily
Once daily
Titration Flow
Start
Choose starting dose based on CKD stage and Hb level.
Assess
Reassess Hb every 2–4 weeks.
Adjust
Increase or decrease dose by 25 mg increments.
Maintain
Maintain target Hb 10–13 g/dL.
Note: Do not increase the dose more frequently than once every 2 weeks.
Evidence that
empowers confidence
Robust clinical data from Phase III trials demonstrate the efficacy and safety of Desidustat in CKD patients on dialysis.
Phase III trial data
Proven Hb improvement
Well tolerated safety profile
Published in peer-reviewed journals
Mean Hb Change Over Time
DesidustatEpoetin Alfa
Data from Phase III trials in CKD patients on dialysis.Publications
Efficacy and safety of desidustat in dialysis patients
2022;16(8):OC01–OC05
HIF-PHI therapy: A new era in anaemia management
2021;36(3):405–413
FAQs
12+
Clinical studies conducted
3000+
Patients studied across trials
Global
Evidence across diverse populations
15+
Peer-reviewed publications and abstracts
Clear answers.
Better conversations.
Find practical information about OXEMIA™, Desidustat, and anaemia management in CKD.
This information does not replace advice from your healthcare professional.
OXEMIA™ contains Desidustat, an oral HIF-PH inhibitor developed for the management of anaemia associated with chronic kidney disease.
Still have a question?
Our medical information team is here to help.
We're here
to help.
For product information, prescribing resources, or medical enquiries, connect with the appropriate Oxemia team.
Call us1800 123 4567
Emailmedical.info@oxemia.com
OfficeZydus Lifesciences Ltd., Ahmedabad, India
How can we support you?
For healthcare professionals
Access detailed prescribing information and medical resources.